Skip to main content
Adaptimmune Therapeutics PLC logo

Adaptimmune Therapeutics PLC — Investor Relations & Filings

Ticker · ADAP ISIN · US00653A1079 LEI · 549300UUNWK8TRT5EW12 US Manufacturing
Open in API
Filings indexed 807 across all filing types
Latest filing 2017-11-02 Interim / Quarterly Rep…
Country GB United Kingdom
Listing US ADAP

About Adaptimmune Therapeutics PLC

https://www.adaptimmune.com/

Adaptimmune Therapeutics is a commercial-stage biopharmaceutical company specializing in the development of novel T-cell receptor (TCR) T-cell therapies for cancer. The company utilizes a proprietary platform to engineer a patient's own T-cells to recognize and fight solid tumors. Its first FDA-approved therapy, Tecelra (afami-cel), is a treatment for advanced synovial sarcoma. Adaptimmune is advancing a robust pipeline of cell therapies, including preclinical programs targeting PRAME and CD70, as well as an allogeneic platform. The company's mission is to deliver transformative, potentially single-infusion treatments to reshape cancer care for patients with difficult-to-treat solid tumors.

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report 9M 2017
2017-11-02 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 2, 2017, reporting the results of operations and financial conditions for the third quarter ended September 30, 2017. It references a press release announcing financial results, attached as Exhibit 99.1. The document itself is short (3865 characters) and primarily serves as a current report announcing the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document is classified as an Earnings Release (ER) because it is the initial announcement of quarterly financial results with key highlights, not a full interim report or annual report. The presence of a press release announcing quarterly results aligns with the ER category.
2017-11-02 English
MATRIX CAPITAL MANAGEMENT COMPANY LP
Major Shareholding Notification
2017-09-11 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes the entry into a material definitive agreement between Adaptimmune Therapeutics and GlaxoSmithKline, detailing the exercise of an option under a collaboration and license agreement. It also includes a press release as an exhibit. There are no financial statements or detailed financial data presented, nor is this a full annual or quarterly report. The document is an announcement of a significant corporate event related to capital and collaboration agreements. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length is over 5,000 characters and contains substantive information about the agreement, not just a brief announcement or a certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2017-09-07 English
10-Q
Interim / Quarterly Report Q2 2017
2017-08-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 3, 2017, reporting the results of operations and financial conditions for the second quarter ended June 30, 2017. It specifically mentions a press release announcing financial results for the quarter, attached as Exhibit 99.1. The document is relatively short (3851 characters) and primarily serves as a current report to announce the earnings release rather than containing detailed financial statements or analysis itself. According to the rules, such a document announcing quarterly financial results is classified as an Earnings Release (ER).
2017-08-03 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.